About: A multicenter surveillance of antimicrobial resistance in Serratia marcescens in Taiwan

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A multicenter surveillance of antimicrobial resistance in Serratia marcescens in Taiwan Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A multicenter surveillance of antimicrobial resistance in Serratia marcescens in Taiwan
Creator	Fung, Chang-Phone Duh, Ruay-Wang Lin, Yi-Tsung Liou, Bo-Huang Lauderdale, Tsai-Ling
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Serratia marcescens is an important nosocomial pathogen and the characteristic property of resistance conferred by extended-spectrum beta-lactamase or a novel AmpC cephalosporinase was not unusual in Taiwan. This study investigated the trends in antimicrobial resistance in S. marcescens from a nationwide surveillance in Taiwan. MATERIALS AND METHODS: S. marcescens isolates were collected biennially between 2002 and 2010 from medical centers and regional hospitals throughout Taiwan, as part of the Taiwan Surveillance of Antimicrobial Resistance program. Minimal inhibitory concentrations were determined by the Clinical and Laboratory Standards Institute reference broth microdilution method. RESULTS: A total of 403 nonduplicate S. marcescens isolates were collected, mostly from respiratory samples (157, 39.0%), followed by the urinary tract samples (90, 22.3%). Overall, 99.3% isolates were susceptible to imipenem, 93.8% to ceftazidime, 89.2% to minocycline, 87.8% to amikacin, 86.8% to cefepime, 82.9% to aztreonam, 73.2% to ceftriaxone, 72.7% to levofloxacin, 63.8% to ciprofloxacin, 60.8% to trimethoprim/sulfamethoxazole (TMP/SMX), and 59.6% to gentamicin. A significantly increased susceptibility rate after 2004 was observed for the following antibiotics: amikacin (73.8% vs. 97.1%), gentamicin (40.0% vs. 72.4%), ciprofloxacin (53.8% vs. 70.4%), ceftriaxone (53.8% vs. 86.0%), cefepime (74.4% vs. 95.1%), aztreonam (72.5% vs. 89.7%), and TMP/SMX (41.3% vs. 73.7%). CONCLUSION: In this 8-year study, the susceptibility of S. marcescens to ceftazidime and imipenem remained consistently high in Taiwan. S. marcescens isolates demonstrated relatively higher resistance to ciprofloxacin and levofloxacin, and therefore continued surveillance of antimicrobial resistance, especially for fluoroquinolone, is warranted.
has issue date	2013-06-14(xsd:dateTime)
bibo:doi	10.1016/j.jmii.2013.04.003
bibo:pmid	23751769
has license	no-cc
sha1sum (hex)	b27ff5023e0a1af4b8d3fe0081381f87fbef660f
schema:url	https://doi.org/10.1016/j.jmii.2013.04.003
resource representing a document's title	A multicenter surveillance of antimicrobial resistance in Serratia marcescens in Taiwan
has PubMed Central identifier	PMC7105062
has PubMed identifier	23751769
schema:publication	J Microbiol Immunol Infect
resource representing a document's body	covid:b27ff5023e0a1af4b8d3fe0081381f87fbef660f#body_text
is schema:about of	named entity 'ciprofloxacin' named entity 'antimicrobial resistance' named entity 'S. marcescens' named entity 'gentamicin' named entity 'Serratia marcescens' covid:arg/b27ff5023e0a1af4b8d3fe0081381f87fbef660f named entity 'ciprofloxacin' named entity 'regional' named entity 'samples' named entity 'imipenem' named entity 'Institute' named entity 'nosocomial' named entity 'aztreonam' named entity 'ceftazidime' named entity 'concentrations' named entity 'study' named entity 'levofloxacin' named entity 'cefepime' named entity 'isolates' named entity 'collected' named entity 'amikacin' named entity 'nationwide' named entity 'TMP' named entity '2004' named entity 'resistance' named entity 'Taiwan' named entity 'Immunology' named entity 'broth microdilution' named entity 'cefepime' named entity 'Serratia marcescens' named entity 'antimicrobial resistance' named entity 'imipenem' named entity 'Taiwan' named entity 'S. marcescens' named entity 'extended-spectrum beta-lactamase' named entity 'TMP/SMX' named entity 'amikacin' named entity 'antimicrobials' named entity 'levofloxacin' named entity 'cefotaxime' named entity 'cefuroxime' named entity 'API' named entity 'tetracycline' named entity 'S. marcescens' named entity 'tigecycline' named entity 'antibiotics' named entity 'b-lactam' named entity 'ciprofloxacin' named entity 'AmpC cephalosporinase' named entity 'medical centers' named entity 'intensive care unit' named entity 'urine' named entity 'medical centers' named entity 'ciprofloxacin' named entity 'cefoxitin' named entity 'Clinical and Laboratory Standards Institute' named entity 'ceftriaxone' named entity 'ICU' named entity 'Taiwan' named entity 'Enterobacteriaceae' named entity 'S. marcescens' named entity 'cefepime' named entity 'chromosomal' named entity 'levofloxacin' named entity 'nosocomial infections' named entity 'Taiwan' named entity 'Minimum inhibitory concentration' named entity 'ampC' named entity 'colistin' named entity 'ampicillin' named entity 'ceftazidime' named entity 'S. marcescens' named entity 'antimicrobial resistance' named entity 'S. marcescens' named entity 'urinary tract infections' named entity 'Serratia marcescens' named entity 'S. marcescens'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software